Table 3. Characteristics of re-irradiated cases.
| Sex/Age | Histology | Location | Volume (cm3) | Previous RT dose (Gy/fx) | SBRT dose (Gy/fx) | Durationa) (M) | OSb) (M) | LCc) (M) | Toxicity y ≥ Gr 3 |
|---|---|---|---|---|---|---|---|---|---|
| F/31 | Synovial sarcoma | Pelvis | 33.7 | 30/10 | 24/3 | 1 | 28 | 14 | None |
| F/52 | Malignant schwannoma | Back | 213.8 | 60/30 | 30/3 | 64 | 27 | 23 | Skind) |
| M/63 | Undifferentiated pleomorphic sarcoma | Pelvis | 9.4 | 60/30 | 40/5 | 25 | 22 | 14 | None |
| F/34 | Myofibroblastic sarcoma | Buttock | 124.6 | 45/15 | 39/3 | 19 | 20 | 4 | None |
| M/31 | Synovial sarcoma | Paraspinal | 59.3 | 20/1 | 30/3 | 20 | 12 | 7 | None |
Abbreviations: RT, radiation therapy; SBRT, stereotactic body radiation therapy; OS, overall survival; M, months; LC, local control; Gr, grade.
a)Duration; duration between previous RT and re-irradiation.
b)All patients expired within 3 years after SBRT.
c)All lesions recurred within 2 years after SBRT.
d)Grade 3 skin toxicity occurred at 10 M after SBRT.